Mechanism of Action
SSTR Activation vs. Unique Targets
Cortistatin activates SSTR1-5 with comparable affinity to somatostatin, mediating inhibition of GH, insulin, glucagon, and GI secretions through Gi-coupled receptor signaling. Unique to cortistatin, it also activates GHS-R1a (the ghrelin/" class="wiki-internal-link">ghrelin receptor) and MrgX2, a mast cell receptor. These additional targets may explain the divergent CNS and immune effects not seen with somatostatin.
Neuroinflammation and Immune Modulation
Cortistatin has potent anti-inflammatory properties mediated through SSTR2 and SSTR3 on immune cells. It inhibits microglial activation, reduces pro-inflammatory cytokine production, and promotes regulatory T cell function. These immunomodulatory effects are being explored for inflammatory and autoimmune conditions.
Research Summary
Sleep Promotion
PreclinicalUnlike somatostatin (which has minimal sleep effects), cortistatin significantly increases slow-wave sleep (SWS) and reduces REM sleep when administered ICV. This distinguishing property mapped to its unique C-terminal sequence not shared with somatostatin. Cortistatin-knockout mice show impaired sleep regulation, establishing its endogenous sleep-promoting role.
Anti-Inflammatory Efficacy
PreclinicalCortistatin treatment reduces disease severity in mouse models of rheumatoid arthritis, Crohn disease, and experimental autoimmune encephalomyelitis (EAE). In systemic inflammatory response syndrome models, cortistatin reduces mortality and cytokine storm parameters. These results have positioned cortistatin as a lead compound for anti-inflammatory drug development.
Calculate your Cortistatin-14 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Sleep induction | 10-100 nmol ICV | Single | Intracerebroventricular |
| Anti-inflammatory | 100-300 mcg/kg | Daily | IV or IP injection |
Preclinical only. No approved human use. Somatostatin analogs (octreotide) target the shared SSTR pathway.
Interactions
Safety Profile
Cortistatin is an endogenous neuropeptide; physiological concentrations are well tolerated. Like somatostatin, exogenous cortistatin would be expected to inhibit GH, insulin, and GI secretions, requiring monitoring for hypoglycemia and nutritional effects. No clinical safety data for cortistatin itself; somatostatin analogs provide a reference safety profile.
References
- [1]de Lecea L et al. (1996). A cortical neuropeptide with neuronal depressant and sleep-modulating properties. Nature, 381(6579), 242-245.
- [2]Gonzalez-Rey E et al. (2006). Cortistatin, a new anti-inflammatory peptide with therapeutic effect on lethal endotoxemia. Journal of Experimental Medicine, 203(3), 563-571.